安科生物(300009.SZ)：PA3-17注射液纳入拟突破性治疗品种

智通财经2025-08-08

智通财经APP讯，安科生物(300009.SZ)公告，公司参股公司博生吉医药科技(苏州)有限公司(简称“博生吉医药”)、博生吉安科细胞技术有限公司(简称“博生吉安科”)自主研发的PA3-17注射液被国家药品监督管理局药品审评中心(CDE)纳入拟突破性治疗品种公示名单，公示期7日。PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的靶向CD7的自体CAR-T细胞治疗产品，用于治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557954433?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-08 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557954433","market":"hk","top_or_hot":-1,"title":"安科生物(300009.SZ)：PA3-17注射液纳入拟突破性治疗品种","media":"智通财经","content":"<div>\n<p>智通财经APP讯，安科生物(300009.SZ)公告，公司参股公司博生吉医药科技(苏州)有限公司(简称“博生吉医药”)、博生吉安科细胞技术有限公司(简称“博生吉安科”)自主研发的PA3-17注射液被国家药品监督管理局药品审评中心(CDE)纳入拟突破性治疗品种公示名单，公示期7日。PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的靶向CD7的自体CAR-T细胞治疗产品，用于治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1327351.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安科生物(300009.SZ)：PA3-17注射液纳入拟突破性治疗品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安科生物(300009.SZ)：PA3-17注射液纳入拟突破性治疗品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-08 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1327351.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，安科生物(300009.SZ)公告，公司参股公司博生吉医药科技(苏州)有限公司(简称“博生吉医药”)、博生吉安科细胞技术有限公司(简称“博生吉安科”)自主研发的PA3-17注射液被国家药品监督管理局药品审评中心(CDE)纳入拟突破性治疗品种公示名单，公示期7日。PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的靶向CD7的自体CAR-T细胞治疗产品，用于治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1327351.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1327351.html","article_id":"2557954433","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557954433","pubTimestamp":1754643617,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司参股公司博生吉医药科技(苏州)有限公司(简称“博生吉医药”)、博生吉安科细胞技术有限公司(简称“博生吉安科”)自主研发的PA3-17注射液被国家药品监督管理局药品审评中心(CDE)纳入拟突破性治疗品种公示名单，公示期7日。PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的靶向CD7的自体CAR-T细胞治疗产品，用于治疗成人复发/难治性T淋巴母细胞白血病/淋巴瘤(R/RT-ALL/LBL)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300009":"安科生物","BK0239":"医药制造","BK0070":"员工持股","BK0060":"抗癌","BK0042":"基因检测"},"translate_title":"Anke Bio (300009. SZ): PA3-17 injection included in the proposed breakthrough therapeutic varieties","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300009":1},"content_text":"智通财经APP讯，安科生物(300009.SZ)公告，公司参股公司博生吉医药科技(苏州)有限公司(简称“博生吉医药”)、博生吉安科细胞技术有限公司(简称“博生吉安科”)自主研发的PA3-17注射液被国家药品监督管理局药品审评中心(CDE)纳入拟突破性治疗品种公示名单，公示期7日。PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的靶向CD7的自体CAR-T细胞治疗产品，用于治疗成人复发/难治性T淋巴母细胞白血病/淋巴瘤(R/RT-ALL/LBL)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557954433","isCrawlerRequest":true}